N. Anthony Coles - 02 Mar 2023 Form 4 Insider Report for Cerevel Therapeutics Holdings, Inc.

Role
CEO and Chairperson, Director
Signature
/s/ Mark Bodenrader, as Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
02 Mar 2023
Net transactions value
-$1,180,947
Form type
4
Filing time
06 Mar 2023, 15:15:28 UTC
Previous filing
08 Feb 2023
Next filing
13 Apr 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CERE Common Stock Options Exercise $164,500 +47,000 +1738% $3.50* 49,704 02 Mar 2023 Direct F1
transaction CERE Common Stock Sale $1,274,377 -47,000 -95% $27.11 2,704 02 Mar 2023 Direct F1, F2
transaction CERE Common Stock Options Exercise $10,500 +3,000 +111% $3.50* 5,704 03 Mar 2023 Direct F1
transaction CERE Common Stock Sale $81,570 -3,000 -53% $27.19 2,704 03 Mar 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CERE Stock Option (Right to Buy) Options Exercise $0 -47,000 -1.6% $0.000000 2,905,417 02 Mar 2023 Common Stock 47,000 $3.50 Direct F1, F3
transaction CERE Stock Option (Right to Buy) Options Exercise $0 -3,000 -0.1% $0.000000 2,902,417 03 Mar 2023 Common Stock 3,000 $3.50 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These transactions were effected pursuant to a Rule 10b5-1 trading plan dated November 9, 2022 adopted by the Reporting Person.
F2 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.62 - $27.48. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 25% of the shares subject to this option vested and became exercisable on November 27, 2019, with remainder vesting in 36 equal monthly installments thereafter.